Contents

Preface *xiii*
A Personal Foreword *xvii*

1 Chemical Strategies for Evaluating New Drug Targets *1*
Adrian J. Carter, Raina Seupel, Paul E. Brennan, Michael Sundström, Andrea Introini, and Anke Mueller-Fahrnow
1.1 Introduction *1*
1.2 Use Cases and Case Studies for Chemogenomic Compounds and Chemical Probes *5*
1.2.1 Chemogenomic Libraries *5*
1.2.2 Inactive Control *6*
1.2.3 Use of Biological Target Panels and Profiling *8*
1.3 Development of Chemical Probes *10*
1.3.1 From BIX01294 to EPZ035544: Development and Improvement of G9a/GLP Inhibitors *10*
1.3.2 Development of BRD9 Inhibitors *12*
1.4 Compound-Based Target Evaluation with Patient-Derived Cells *14*
1.4.1 Compound-Based Target Evaluation *14*
1.4.2 Patient-Derived Cell Assays *16*
1.4.3 Target Evaluation Approach *16*
1.4.4 Case Story: Inflammatory Bowel Disease (IBD) Tissue Platform *18*
1.5 Summary and Outlook *19*
References *20*

2 Affinity-Based Chemoproteomics for Target Identification *25*
Annika Jenmalm Jensen and Ivan Cornella Taracido
2.1 Introduction *25*
2.2 Small Molecule Phenotypic Mechanism of Action Elucidation *29*
2.3 Quantitative High-Resolution Mass Spectrometry as a Protein Detection Read-Out *30*
2.4 In-Lysate Affinity-Based Chemical Proteomics *33*
2.4.1 Design of the Affinity Probe *34*
2.4.2 General Experimental Pulldown Workflow *36*
2.4.3 Limitations *38*

2.5 In-Cell Light-Activated Affinity-Based Chemoproteomics *39*
2.5.1 Design of the Reactive Photoaffinity Probe (PAL Probe) *40*
2.5.2 General Experimental Workflow *40*
2.5.3 Limitations *43*
2.6 Target Validation and Mode of Action *43*
2.7 Concluding Remarks *45*
References *46*

3 Activity-Based Protein Profiling *51*
Nattawadee Panyain, Cassandra R. Kennedy, Ryan T. Howard, and Edward W. Tate
3.1 Introduction *51*
3.2 Activity-Based Probe (ABP) and Affinity-Based Probe (AfBP) Design *53*
3.2.1 Warheads (Reactive Groups) *53*
3.2.1.1 Electrophilic Warheads *55*
3.2.1.2 Photocrosslinking Warheads *55*
3.2.2 Reporter Tags *56*
3.2.3 Linkers *56*
3.2.4 Bioorthogonal Ligation Chemistry *57*
3.2.4.1 Staudinger Ligation *58*
3.2.4.2 Copper(I)-Catalysed Azide-Alkyne Cycloaddition (CuAAC) *58*
3.2.4.3 Strain-Promoted Azide-Alkyne Cycloaddition (SPAAC) *59*
3.2.4.4 Diels–Alder Reaction *59*
3.3 Chemical Proteomic Workflow *60*
3.3.1 Quantitative Proteomics by Mass Spectrometry *61*
3.3.1.1 Label-Free Quantification (LFQ) *61*
3.3.1.2 Chemical Labelling Quantification *61*
3.3.1.3 Metabolic Labelling Quantification *63*
3.4 ABPP Applications and Case Studies *63*
3.4.1 Case Study 1: Activity-Based Protein Profiling as a Robust Method for Enzyme Identification and Screening in Extremophilic Archaea *65*
3.4.2 Case Study 2: Failed Clinical Trial of a Fatty Acid Amide Hydrolase (FAAH) Inhibitor *68*
3.4.3 Case Study 3: Target Identification of Small Molecule Inhibitors *71*
3.4.3.1 New Target Profiling for Sulforaphane *71*
3.4.3.2 Profiling USP Inhibitors in Human Cell Lines as Potential Therapeutic Molecules *73*
3.4.4 Case Study 4: Fragment-Based Ligand Discovery Aided by Photoaffinity Labelling *74*
3.4.5 Case Study 5: Quenched Fluorescent Activity-Based Probe (qABP) Design and Application in Protein Localization *80*
3.5 Summary *82*
References *83*

4 Kinobeads: A Chemical Proteomic Approach for Kinase Inhibitor Selectivity Profiling and Target Discovery *97*
Maria Reinecke, Stephanie Heinzlmeir, Mathias Wilhelm, Guillaume Médard, Susan Klaeger, and Bernhard Kuster
4.1 Kinase Inhibitor Target Deconvolution Using Chemical Proteomics *97*
4.1.1 Polypharmacology of Small Molecule Kinase Inhibitors *97*
4.1.2 Chemoproteomic Profiling of Kinase Inhibitors *100*
4.1.3 Tips and Tricks Regarding Chemoproteomic Assay Development *103*
4.2 Detailed Kinobeads Protocol *105*
4.2.1 Cell or Tissue Lysate *107*
4.2.2 Affinity Matrices *107*
4.2.3 Kinobeads Competition Assay *110*
4.2.4 Mass Spectrometry *111*
4.2.5 Peptide and Protein Identification and Quantification *112*
4.2.6 Data Analysis *112*
4.3 Application Examples for Kinobeads *113*
4.3.1 Expanding the Target Space of Kinobeads *113*
4.3.2 Target Space Deconvolution of Small Molecule Kinase Inhibitors *116*
4.3.3 Opportunities Arising from Inhibitor Polypharmacology: Drug Repositioning *120*
4.3.4 Chemoproteomic-Guided Medicinal Chemistry *121*
4.4 Kinobeads, Inhibitors, and Drug Discovery: Where Are We Heading? *123*
4.4.1 What Is a Good Drug? *123*
4.4.2 How Can We Discover New Drugs in the Future? *124*
4.4.3 The Yin and Yang of Chemoproteomic-Guided Drug Discovery *124*
Acknowledgments *125*
References *125*

5 Label-Free Techniques for Target Discovery and Validation *131*
Daniel Martinez Molina and Michael Dabrowski
5.1 Introduction *131*
5.2 CETSA: How It All Began *132*
5.3 The CETSA Formats *136*
5.3.1 CETSA Classics *136*
5.3.2 CETSA HT *138*
5.3.3 CETSA MS *140*
5.4 Target Discovery *142*
5.4.1 Generation of Active Hit Molecules *142*
5.4.2 Tool Generation (Small Screens to Identify Tool Compounds) *143*
5.4.3 Target Classes That Are In and Out of Scope and Difficult Targets *143*
5.4.4 Focused or Iterative Library Screening *144*

5.4.5 Fragment Library Screening *144*
5.4.6 Hit Confirmation *145*
5.4.7 Phenotypic Hit Deconvolution to Discover Targets *145*
5.5 Target Validation *147*
5.5.1 Binding Modes *147*
5.5.2 Selectivity, Specificity, and Safety *148*
5.5.3 Translation Bench to Bedside (via Animals) *149*
5.6 Conclusion *150*
References *151*

6 Reverse Translation to Support Efficient Drug Target Selection and Stratified Medicine *153*
Lauren Drowley and Martin Armstrong
6.1 Introduction: the Challenge *153*
6.2 Genetics to Date in Drug Discovery *154*
6.3 Genetic Strategies for Target Discovery *156*
6.3.1 GWAS *158*
6.3.2 Rare Disease Genetics *160*
6.3.2.1 Rare Mutation → Rare Disease Drug Discovery *161*
6.3.2.2 Rare Mutation → Common Disease Drug Discovery *161*
6.3.3 Somatic Mutations *162*
6.3.4 Analytical Approaches *163*
6.4 Functional Validation *164*
6.4.1 Prioritization of Putative Mutations *165*
6.4.2 Determining Functional Consequence of Mutation *165*
6.4.2.1 Publicly Available Data *165*
6.4.2.2 Systems Biology *166*
6.4.2.3 Model Systems: 'The Tissue Is the Issue' *168*
6.4.3 Druggability: From Validation of a Gene to a Druggable Target *169*
6.5 Forward-Looking Perspectives *170*
6.5.1 Molecular Taxonomy of Disease *171*
6.5.2 Precision Medicine *171*
6.5.3 Data Integration *172*
6.6 Conclusion *173*
References *173*

7 Elucidating Target Biology and Drug Mechanism of Action Across Human Cell-Based Model Systems *179*
John C. Dawson and Neil O. Carragher
7.1 Introduction *179*
7.2 Advances in Human Cell-Based Model Development *182*
7.2.1 Next-Generation Sequencing (NGS) *183*
7.2.2 CRISPR Genome Editing *184*
7.2.3 Induced Pluripotent Stem Cell Biology *184*
7.2.4 3D Cell and Organoid Models *185*
7.2.5 Microfluidic and Organ-on-a-Chip Devices *186*
7.2.6 *In Vivo* Imaging *188*

7.2.7 High-Content Imaging *190*
7.3 Multiparametric High-Content Phenotypic Profiling of Target Biology and Drug Mechanism of Action *191*
7.3.1 High-Content Cell Painting in Functional Genomics *193*
7.3.2 Integration of Multiparametric High-Content Imaging with Chemoinformatics *195*
7.3.3 Guiding Chemical Design and Target Selectivity from Multiparametric High-Content Analysis *195*
7.4 Target-Annotated Compound Libraries for Phenotypic Screening and MOA Determination *196*
7.5 Quantitative Pathway Profiling Across New Model Systems *197*
7.5.1 Pathway Profiling at the Gene Transcription Level *198*
7.5.2 Dynamic Post-Translational Pathway Profiling Across Dose–Response and Time-Series Studies *199*
7.6 Conclusions *202*
References *203*

8 Cell Biology Methods in Target Validation *211*
Manfred Koegl and Simon Wöhrle
8.1 Introduction *211*
8.2 Biomarkers *211*
8.2.1 Direct Target Engagement Biomarkers *212*
8.2.2 Indirect Target Engagement Biomarkers and Pathway Biomarkers *213*
8.2.3 Response Biomarkers *214*
8.2.4 Correlation of Biomarkers *214*
8.3 Direct Evidence to Show That Modulation of a Target Leads to a Cellular Response *219*
8.4 Direct Evidence That Target Modulation Is Responsible for Cellular Responses by Mutations Conferring Sensitivity to Existing Drugs *219*
8.4.1 The 'Bump-and-Hole' Approach to Generate Sensitivity to Small Molecule Inhibitors *219*
8.4.2 Chemogenomic Approaches for Inducible Degradation of Protein Targets *222*
8.5 Resistance Conferring Mutations *226*
References *229*

9 Genetic Manipulation/Modulation for Target Discovery and Validation *233*
Christophe Lanneau, Georges Kalouche, Xinming Cai, Francois Lo-Presti, and Christoph Potting
9.1 Introduction *233*
9.2 Overview of the Development of Leading Genetic Manipulation Technologies *234*
9.2.1 RNAi, ZFNs, and TALENs *234*
9.2.2 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) *237*

9.3 Considerations for Designing and Interpreting CRISPR Experiments *238*
9.3.1 Methodological Considerations for Genetic Manipulation by the CRISPR/Cas Technology *238*
9.3.2 Choosing a Cellular Model: Biological and Genomic Aspects *239*
9.3.3 gRNA Design *242*
9.3.3.1 Identification of Target Locations *242*
9.3.3.2 Selection of Spacer Sequences *245*
9.3.3.3 Predictive Tools *247*
9.3.4 Successful Application of the CRISPR/Cas Technology *249*
9.3.4.1 Delivering CRISPR Reagents to Target Cells *249*
9.3.4.2 Check for Anticipated Knockout/Knock-In *252*
9.4 Further Developments of the CRISPR/Cas Technology Facilitates Additional Modes of Genetic Perturbation *253*
9.4.1 CRISPRi *253*
9.4.2 CRISPRa *253*
9.4.3 Base Editing *254*
9.5 The CRISPR/Cas Technology in Target Discovery and Validation *254*
9.5.1 CRISPR/Cas Technology for Early Target Validation *254*
9.5.2 CRISPR Screens and Use for Target Discovery *255*
9.5.3 CRISPR Screens: General Principle and Considerations *256*
9.5.4 Selected Examples of Target Discovery Using CRISPR Screens to Illustrate the Breadth of Applications *258*
9.6 Application of CRISPR Genome Editing in Immunology Studies *260*
9.7 Concluding Remarks *262*
References *263*

10 Computational Approaches for Target Inference *277*
Gerhard Hessler, Christoph Grebner, and Hans Matter
10.1 Introduction *277*
10.2 Data Annotation for Target Identification *278*
10.3 *In Silico* Methods for Target Identification *280*
10.3.1 2D Similarity Methods for Target Inference *283*
10.3.2 3D Similarity Methods for Target Inference *289*
10.3.3 Fragment-Based Approaches *290*
10.3.4 QSAR Models and Machine Learning *292*
10.3.5 Experimentally Derived Molecular Descriptors *297*
10.3.6 Structure-Based Screening *299*
10.3.7 Protein–Protein and Ligand–Target Networks *302*
10.4 Practical Considerations *304*
10.5 Conclusion *307*
References *308*

11 Bioinformatic Approaches in the Understanding of Mechanism of Action (MoA) *323*
Maria-Anna Trapotsi, Ian Barrett, Ola Engkvist, and Andreas Bender
11.1 Bioinformatics: Introduction *323*

11.1.1 Some Definitions: Mechanism Versus Mode of Action *323*
11.1.2 Importance of MoA and Target Prediction in the Drug Discovery Process *324*
11.1.3 Different Levels of Information in Mechanism of Action and Target Prediction *325*
11.2 Transcriptomics Data and Databases *326*
11.2.1 Biological Background of the Transcription Process *326*
11.2.2 Connectivity Map: CMap *327*
11.2.2.1 Applications of CMap in MoA Deconvolution *328*
11.2.3 Library of Integrated Network-Based Cellular Signatures (LINCS) *331*
11.2.3.1 LINCS L1000 Data Exploration *332*
11.2.3.2 Applications of L1000 Data in MoA Understanding *333*
11.3 Pathway Data and Databases *339*
11.3.1 What Is a Pathway? *339*
11.3.2 Process of Pathway Analysis *341*
11.3.3 Pathways in the Understanding of MoA *345*
11.3.3.1 Methodology 1: MoA Analysis by Annotating Predicted Compounds' Targets with Pathways *345*
11.3.4 Combination of Gene Expression and Pathway Data *346*
11.3.4.1 Methodology 2: Construction of Drug Networks (DNs) with Gene Expression Data and Pathway Annotations *346*
11.3.4.2 Methodology 3: Link Drug Target and Pathway Activation to Understand MoA *347*
11.4 Image-Based Data *348*
11.4.1 Image Data and Where to Extract Them From *348*
11.4.2 Application of Image-Based Data in Target Prediction and Better Understanding of MoA *350*
11.4.2.1 Methodology 1: Clustering of Compounds Based on Cell Morphology *350*
11.4.2.2 Methodology 2: Use of Image-Based Data in the Development of a Cell Morphology Database That Can Facilitate Drug Target Identification *350*
11.4.2.3 Methodology 3: Use of Image Data in Drug Repositioning and Biological Activity Prediction *353*
11.4.2.4 Methodology 4: Association of Genes with Context-Dependent Morphology Alterations from Cells Exposed to Chemical or Genetic Perturbations for MoA Elucidation *354*
11.5 Conclusions *357*
Acknowledgement *357*
References *357*

Index *365*